DK0524968T3 - Heterovesikulære lipidvesikler - Google Patents

Heterovesikulære lipidvesikler

Info

Publication number
DK0524968T3
DK0524968T3 DK91906733.0T DK91906733T DK0524968T3 DK 0524968 T3 DK0524968 T3 DK 0524968T3 DK 91906733 T DK91906733 T DK 91906733T DK 0524968 T3 DK0524968 T3 DK 0524968T3
Authority
DK
Denmark
Prior art keywords
emulsion
lipid vesicles
vial
composition
heterovesicular
Prior art date
Application number
DK91906733.0T
Other languages
Danish (da)
English (en)
Inventor
Sinil Kim
Original Assignee
Depotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depotech Corp filed Critical Depotech Corp
Application granted granted Critical
Publication of DK0524968T3 publication Critical patent/DK0524968T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Saccharide Compounds (AREA)
DK91906733.0T 1990-03-21 1991-03-20 Heterovesikulære lipidvesikler DK0524968T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49684690A 1990-03-21 1990-03-21

Publications (1)

Publication Number Publication Date
DK0524968T3 true DK0524968T3 (da) 1995-07-31

Family

ID=23974416

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91906733.0T DK0524968T3 (da) 1990-03-21 1991-03-20 Heterovesikulære lipidvesikler

Country Status (20)

Country Link
EP (1) EP0524968B1 (pt)
JP (1) JP3461000B2 (pt)
KR (1) KR100203223B1 (pt)
CN (1) CN1053101C (pt)
AT (1) ATE123412T1 (pt)
AU (1) AU655177B2 (pt)
CA (1) CA2078666C (pt)
DE (1) DE69110281T2 (pt)
DK (1) DK0524968T3 (pt)
ES (1) ES2073164T3 (pt)
FI (1) FI104464B (pt)
IE (1) IE62772B1 (pt)
IL (1) IL97615A (pt)
NO (1) NO304576B1 (pt)
NZ (1) NZ237464A (pt)
PT (1) PT97101B (pt)
RU (1) RU2120795C1 (pt)
SA (1) SA93130496B1 (pt)
WO (1) WO1991014445A1 (pt)
ZA (1) ZA911974B (pt)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3278273B2 (ja) * 1993-12-17 2002-04-30 キヤノン株式会社 薬剤徐放性カプセル
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
EP1365028B1 (en) 1996-12-13 2009-03-18 Novartis Vaccines and Diagnostics, Inc. Method for expression of PDGF or IGF proteins in yeast
US5985214A (en) 1997-05-16 1999-11-16 Aurora Biosciences Corporation Systems and methods for rapidly identifying useful chemicals in liquid samples
JP4467789B2 (ja) 1997-09-18 2010-05-26 パシラ ファーマシューティカルズ インコーポレーテッド 持続放出性リポソーム麻酔組成物
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
IL135989A0 (en) 1997-11-14 2001-05-20 Skyepharma Inc Processes for the production of multivesicular liposomes
DE69941567D1 (de) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
CN101293920B (zh) 1998-05-01 2012-07-18 诺华疫苗和诊断公司 脑膜炎奈瑟球菌抗原和组合物
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US20030008284A1 (en) 2000-06-15 2003-01-09 Giulia Kennedy Polynucleotides related to colon cancer
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
AU784203B2 (en) 1999-10-29 2006-02-23 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
ES2335386T3 (es) 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. Gen fgf-21 humano y productos de expresion genica.
RU2279889C2 (ru) 2000-01-17 2006-07-20 Чирон С.Р.Л. ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
EP1261638A2 (en) 2000-03-08 2002-12-04 Chiron Corporation Human fgf-23 gene and gene expression products
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
EP1415005B1 (en) 2000-12-07 2012-11-21 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
US7309783B2 (en) 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
KR20030022094A (ko) 2001-05-24 2003-03-15 (주)휴먼디엔에이테크놀로지 모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체
AU2002359446B2 (en) 2001-11-09 2008-12-04 Georgetown University Novel isoforms of vascular endothelial cell growth inhibitor
JP4413617B2 (ja) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Chlamydiatrachomatisに対する免疫化
EP1472375B1 (en) 2002-01-08 2009-04-01 Novartis Vaccines and Diagnostics, Inc. Gene products differentially expressed in cancerous breast cells and their methods of use
US20040023267A1 (en) 2002-03-21 2004-02-05 Morris David W. Novel compositions and methods in cancer
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003288660A1 (en) 2002-11-15 2004-06-15 Chiron Srl Unexpected surface proteins in neisseria meningitidis
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
WO2004058184A2 (en) 2002-12-24 2004-07-15 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
WO2004074321A2 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
EP1594441B1 (en) 2003-02-19 2010-12-15 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
US20070104809A1 (en) 2003-08-22 2007-05-10 Danisco A/S Composition comprising a bacteriocin and an extract from a plant of the labiatae family
CA2551097A1 (en) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Agonist anti-trkc antibodies and methods using same
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
PL1732949T3 (pl) 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
EP1789593B1 (en) 2004-07-09 2017-03-15 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra virus g glycoprotein
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
RU2404750C2 (ru) 2004-11-23 2010-11-27 Адамас Фармасьютикалс, Инк. Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006058236A2 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
ES2385045T3 (es) 2005-02-18 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Inmunógenos de Escherichia coli uropatogénica
CA2604052C (en) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
US20090214536A1 (en) 2005-04-07 2009-08-27 Guoying Yu CACNA1E in Cancer Diagnosis, Detection and Treatment
US20090220495A1 (en) 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
EP1907425B1 (en) 2005-07-22 2014-01-08 Y's Therapeutics Co., Ltd. Anti-cd26 antibodies and methods of use thereof
ES2664854T3 (es) 2005-11-14 2018-04-23 Teva Pharmaceuticals International Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina para tratar cefalea en racimos
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
SG10201604649SA (en) 2006-06-07 2016-07-28 Bioalliance Cv Antibodies Recognizing A Carbohydrate Containing Epitope On CD-43 And Cea Expressed On Cancer Cells And Methods Using Same
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
WO2008116032A1 (en) 2007-03-21 2008-09-25 Effat Emamian Compositions and methods for inhibiting tumor cell growth
EP2155777A2 (en) 2007-04-10 2010-02-24 The Administrators of the Tulane Educational Fund Soluble and membrane-anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR101499278B1 (ko) 2007-12-17 2015-03-06 화이자 리미티드 간질성 방광염의 치료
JP5568478B2 (ja) 2007-12-18 2014-08-06 バイオアライアンス セー.フェー. 癌細胞で発現するcd−43およびceaの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
US10000568B2 (en) 2008-04-10 2018-06-19 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9拮抗劑類
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
CN109248313B (zh) 2009-04-14 2023-01-17 葛兰素史密丝克莱恩生物有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
ES2662716T3 (es) 2009-07-07 2018-04-09 Glaxosmithkline Biologicals Sa Inmunógenos conservados de Escherichia coli
MX2012000734A (es) 2009-07-16 2012-01-27 Novartis Ag Inmunogenos destoxificados de escherichia coli.
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
SA114360064B1 (ar) 2010-02-24 2016-01-05 رينات نيوروساينس كوربوريشن طرق وأجسام مضادة معارضة ضد مستقبل il-7
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US9770414B2 (en) * 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
BR112014011331A2 (pt) 2011-11-11 2017-04-25 Rinat Neuroscience Corp anticorpos específicos para trop-2 e seus usos
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
IN2014CN04652A (pt) 2011-12-22 2015-09-18 Rinat Neuroscience Corp
US20150191702A1 (en) 2012-07-02 2015-07-09 Commonwealth Scientific And Industrial Research Organization Paramyxovirus and Methods of Use
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
CA2890483A1 (en) 2012-11-09 2014-05-15 Robert ARCH Platelet-derived growth factor b specific antibodies and compositions and uses thereof
CA2906624A1 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
SG11201508264UA (en) 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR102048718B1 (ko) 2013-08-02 2019-11-26 화이자 인코포레이티드 항-cxcr4 항체 및 항체-약물 접합체
BR112016009797A2 (pt) 2013-11-13 2017-12-05 Bristol Myers Squibb Co anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
SI3119431T1 (sl) 2014-03-21 2024-06-28 Teva Pharmaceuticals International Gmbh Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
PL3283106T3 (pl) 2015-04-13 2022-05-02 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
KR20180096567A (ko) 2015-07-21 2018-08-29 다이액스 코포레이션 Xiia 인자의 단일클론 항체 저해제
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
PE20180556A1 (es) 2015-08-19 2018-04-02 Pfizer Anticuerpos inhibidores via del factor tisular y usos de los mismos
CN113896789A (zh) 2015-09-15 2022-01-07 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
JP6661319B2 (ja) * 2015-09-28 2020-03-11 小林製薬株式会社 リポソーム
EP3365369A1 (en) 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技(上海)有限公司 抗pd-1抗体及其治疗用途
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ, インコーポレイテッド 発作−関連障害の処置のための方法および組成物
WO2017125831A1 (en) 2016-01-21 2017-07-27 Pfizer Inc. Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
JP2020510435A (ja) 2017-03-03 2020-04-09 ライナット ニューロサイエンス コーポレイション 抗gitr抗体およびその使用方法
EP3596206A1 (en) 2017-03-16 2020-01-22 Pfizer Inc Tyrosine prototrophy
EP3610010A4 (en) 2017-04-14 2021-02-24 Kodiak Sciences Inc. COMPLEMENT D-FACTOR ANTAGONIST ANTIBODIES AND THEIR CONJUGATES
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
US11421040B2 (en) 2017-06-02 2022-08-23 Pfizer Inc. Antibodies specific for FLT3 and their uses
KR102396784B1 (ko) 2017-06-13 2022-05-13 보스턴진 코포레이션 분자 기능적 프로파일을 생성하고, 시각화하고, 분류하는 시스템 및 방법
WO2019014418A1 (en) 2017-07-13 2019-01-17 Massachusetts Institute Of Technology TARGETING THE HDAC2-SP3 COMPLEX TO ENHANCE SYNAPTIC FUNCTION
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
KR20210027230A (ko) 2017-10-04 2021-03-10 옵코 파마슈티칼스, 엘엘씨 암의 개인 맞춤형 치료에 관한 물품 및 방법
MX2020008184A (es) 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
KR20200115596A (ko) 2018-02-01 2020-10-07 화이자 인코포레이티드 Cd70에 특이적인 항체 및 이의 용도
SG11202007518RA (en) 2018-02-28 2020-09-29 Pfizer Il-15 variants and uses thereof
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
SG11202010580TA (en) 2018-05-23 2020-12-30 Pfizer Antibodies specific for cd3 and uses thereof
CN113286634A (zh) 2018-05-23 2021-08-20 辉瑞公司 对gucy2c特异性的抗体及其用途
US20210005284A1 (en) 2019-07-03 2021-01-07 Bostongene Corporation Techniques for nucleic acid data quality control
AU2020363372A1 (en) 2019-10-07 2022-05-19 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CA3152623A1 (en) 2019-10-11 2021-04-15 Richard D. Cummings Anti-tn antibodies and uses thereof
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
JP2023533793A (ja) 2020-07-17 2023-08-04 ファイザー・インク 治療用抗体およびそれらの使用
WO2022023972A1 (en) 2020-07-30 2022-02-03 Pfizer Inc. Cells having gene duplications and uses thereof
AU2021338361A1 (en) 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
US20220180972A1 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
JP2024517745A (ja) 2021-04-29 2024-04-23 ボストンジーン コーポレイション 複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
AU2023213817A1 (en) 2022-01-31 2024-08-01 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
CH624011A5 (pt) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
EP0199362A3 (en) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology System and apparatus for delayed and pulsed release of biologically active substances
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes

Also Published As

Publication number Publication date
EP0524968A4 (en) 1993-03-24
IL97615A (en) 1995-06-29
RU2120795C1 (ru) 1998-10-27
AU655177B2 (en) 1994-12-08
JPH05507680A (ja) 1993-11-04
NO923624L (no) 1992-09-17
NO304576B1 (no) 1999-01-18
SA93130496B1 (ar) 2004-08-14
DE69110281T2 (de) 1995-11-09
FI924193A0 (fi) 1992-09-18
DE69110281D1 (de) 1995-07-13
IE62772B1 (en) 1995-02-22
PT97101B (pt) 1998-08-31
ATE123412T1 (de) 1995-06-15
CN1053101C (zh) 2000-06-07
JP3461000B2 (ja) 2003-10-27
CA2078666A1 (en) 1991-09-22
WO1991014445A1 (en) 1991-10-03
ES2073164T3 (es) 1995-08-01
ZA911974B (en) 1994-08-22
FI104464B (fi) 2000-02-15
NZ237464A (en) 1995-02-24
NO923624D0 (no) 1992-09-17
AU7580691A (en) 1991-10-21
CA2078666C (en) 2001-10-02
EP0524968A1 (en) 1993-02-03
FI924193A (fi) 1992-09-18
KR100203223B1 (ko) 1999-06-15
CN1055663A (zh) 1991-10-30
EP0524968B1 (en) 1995-06-07
IE910911A1 (en) 1991-09-25
IL97615A0 (en) 1992-06-21
PT97101A (pt) 1991-11-29

Similar Documents

Publication Publication Date Title
DK0524968T3 (da) Heterovesikulære lipidvesikler
FI922151A (fi) Metall-peptidkompositioner och metoder foer stimulering av haortillvaext.
ATE82495T1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
DE3775783D1 (de) Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
DE3679204D1 (de) Verfahren zur herstellung kleiner vesikel durch mikroemulgierung.
ATE71834T1 (de) Liposomzubereitung und ihre herstellung.
MX9305444A (es) Derivados de rodanina como agentes hipoglucemicos y para el tratamiento de la enfermedad de alzheimer, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
ATE20574T1 (de) Pulverfoermige mischung von lipiden und hydrophoben bestandteilen, verfahren zu deren herstellung, hydratierte lamellare lipide phasen und verfahren zur herstellung, pharmazeutische oder kosmetische mittel die hydratierte lamellare lipide phasen enthalten.
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
HK160995A (en) Complex compounds of bioflavonoids with phospholipids their preparation and use and pharmaceutical and cosmetic compositions containing them
DE69624485D1 (de) Verfahren zur herstellung hydro-monobenzoporhyrin -photosensibilisatoren enthaltender liposomen
KR900701174A (ko) 인지질-함유 조성물, 이의 제조방법 및 이의 약제학적 물질용 부형제로서의 용도
ES2085920T3 (es) Liposomas dirigidos y metodos de acoplamiento liposoma-proteina.
ATE50695T1 (de) Emulgiermittelkonzentrate fuer wasser in fluechtigen siliconemulsionen, deren anwendung fuer kosmetische zubereitungen un deren herstellung.
ES2042437T1 (es) Procedimiento de preparacion de una lipoproteina modificaa por incorporacion de una substancia activa lipofila.
DE2961609D1 (en) Sila-substituted 1,4-dihydropyridine derivatives, processes for their preparation, pharmaceutical compositions and process for their preparation
ES2041617T3 (es) Productos intermedios para agentes de quelacion con simetria prefijada y procedimiento para su preparacion.
PT79649A (en) Process for preparing pharmaceutical compositions for therapeutical treatment of rheumatic diseases containing oxicam derivatives and 1,2-diacylglycero-3-phosphocholine
SE8302580L (sv) Substituerade iminoderivat av dihydrobensopyran och dihydrobensotiopyran och forfarande for deras framstellning
IL82925A0 (en) Tetrahydrobenzothiazoles,their preparation and pharmaceutical compositions containing them
SE8503447D0 (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
FR2595703B1 (fr) Nouveaux phospholipides, leur procede et les intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
PT72247A (fr) Procede de preparation de nouveaux derives de l'amino-1 propanol-2 et leur application en therapeutique
RU1216844C (ru) Способ стимул ции охоты у крупного рогатого скота